nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Epirubicin—testicular cancer	0.202	1	CrCtD
Doxorubicin—Anthracyclines—Epirubicin—testicular cancer	0.119	0.438	CiPCiCtD
Doxorubicin—Topoisomerase Inhibitors—Etoposide—testicular cancer	0.0905	0.333	CiPCiCtD
Doxorubicin—Topoisomerase Inhibitors—Epirubicin—testicular cancer	0.0623	0.229	CiPCiCtD
Doxorubicin—Daunorubicin—Epirubicin—testicular cancer	0.0428	0.333	CrCrCtD
Doxorubicin—Valrubicin—Epirubicin—testicular cancer	0.0428	0.333	CrCrCtD
Doxorubicin—Idarubicin—Epirubicin—testicular cancer	0.0428	0.333	CrCrCtD
Doxorubicin—urinary bladder cancer—testicular cancer	0.0321	0.174	CtDrD
Doxorubicin—prostate cancer—testicular cancer	0.0314	0.17	CtDrD
Doxorubicin—muscle cancer—testicular cancer	0.0272	0.148	CtDrD
Doxorubicin—ovarian cancer—testicular cancer	0.0272	0.148	CtDrD
Doxorubicin—kidney cancer—testicular cancer	0.0228	0.124	CtDrD
Doxorubicin—lung cancer—testicular cancer	0.022	0.119	CtDrD
Doxorubicin—sarcoma—testicular cancer	0.0217	0.118	CtDrD
Doxorubicin—YWHAG—Epirubicin—testicular cancer	0.0177	0.119	CbGbCtD
Doxorubicin—AURKA—Epirubicin—testicular cancer	0.0177	0.119	CbGbCtD
Doxorubicin—DHCR7—Epirubicin—testicular cancer	0.0177	0.119	CbGbCtD
Doxorubicin—ABCC6—Dactinomycin—testicular cancer	0.00935	0.0627	CbGbCtD
Doxorubicin—NQO1—Carboplatin—testicular cancer	0.00751	0.0504	CbGbCtD
Doxorubicin—NQO1—Cisplatin—testicular cancer	0.00642	0.0431	CbGbCtD
Doxorubicin—ABCC6—Vinblastine—testicular cancer	0.00586	0.0393	CbGbCtD
Doxorubicin—ABCC6—Cisplatin—testicular cancer	0.00537	0.036	CbGbCtD
Doxorubicin—ABCC6—Etoposide—testicular cancer	0.00528	0.0354	CbGbCtD
Doxorubicin—ABCC10—Etoposide—testicular cancer	0.00403	0.0271	CbGbCtD
Doxorubicin—XDH—Carboplatin—testicular cancer	0.00393	0.0264	CbGbCtD
Doxorubicin—TOP2A—Epirubicin—testicular cancer	0.0036	0.0242	CbGbCtD
Doxorubicin—XDH—Cisplatin—testicular cancer	0.00336	0.0225	CbGbCtD
Doxorubicin—TOP2A—Etoposide—testicular cancer	0.00281	0.0188	CbGbCtD
Doxorubicin—ABCC1—Dactinomycin—testicular cancer	0.00276	0.0185	CbGbCtD
Doxorubicin—ABCC10—Methotrexate—testicular cancer	0.00266	0.0179	CbGbCtD
Doxorubicin—ABCC3—Cisplatin—testicular cancer	0.00258	0.0173	CbGbCtD
Doxorubicin—ABCC3—Etoposide—testicular cancer	0.00254	0.017	CbGbCtD
Doxorubicin—ABCB11—Vinblastine—testicular cancer	0.00243	0.0163	CbGbCtD
Doxorubicin—ABCC1—Epirubicin—testicular cancer	0.002	0.0134	CbGbCtD
Doxorubicin—ABCG2—Dactinomycin—testicular cancer	0.00185	0.0124	CbGbCtD
Doxorubicin—ABCC1—Vinblastine—testicular cancer	0.00173	0.0116	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—testicular cancer	0.00168	0.0112	CbGbCtD
Doxorubicin—ABCC1—Etoposide—testicular cancer	0.00156	0.0104	CbGbCtD
Doxorubicin—CYP2B6—Ifosfamide—testicular cancer	0.00153	0.0103	CbGbCtD
Doxorubicin—ABCC2—Carboplatin—testicular cancer	0.00137	0.00921	CbGbCtD
Doxorubicin—ABCC2—Vinblastine—testicular cancer	0.00128	0.00858	CbGbCtD
Doxorubicin—ABCG2—Carboplatin—testicular cancer	0.00124	0.00832	CbGbCtD
Doxorubicin—ABCC2—Cisplatin—testicular cancer	0.00117	0.00787	CbGbCtD
Doxorubicin—ABCC2—Etoposide—testicular cancer	0.00115	0.00773	CbGbCtD
Doxorubicin—NOS3—vein—testicular cancer	0.00114	0.0756	CbGeAlD
Doxorubicin—ABCG2—Cisplatin—testicular cancer	0.00106	0.00711	CbGbCtD
Doxorubicin—ABCG2—Etoposide—testicular cancer	0.00104	0.00699	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—testicular cancer	0.00103	0.0069	CbGbCtD
Doxorubicin—CBR3—NRF2 pathway—SLC2A6—testicular cancer	0.000953	0.144	CbGpPWpGaD
Doxorubicin—ABCC2—Methotrexate—testicular cancer	0.000761	0.00511	CbGbCtD
Doxorubicin—CYP2B6—Cisplatin—testicular cancer	0.000746	0.005	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—testicular cancer	0.000688	0.00462	CbGbCtD
Doxorubicin—ABCB1—Dactinomycin—testicular cancer	0.000666	0.00447	CbGbCtD
Doxorubicin—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000623	0.094	CbGpPWpGaD
Doxorubicin—SLC22A16—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000526	0.0794	CbGpPWpGaD
Doxorubicin—CBR3—embryo—testicular cancer	0.000483	0.0322	CbGeAlD
Doxorubicin—CYP3A4—Ifosfamide—testicular cancer	0.000471	0.00316	CbGbCtD
Doxorubicin—CBR3—seminal vesicle—testicular cancer	0.000454	0.0302	CbGeAlD
Doxorubicin—SLC22A16—gonad—testicular cancer	0.000438	0.0292	CbGeAlD
Doxorubicin—ABCB1—Vinblastine—testicular cancer	0.000417	0.0028	CbGbCtD
Doxorubicin—CYP2D6—Vinblastine—testicular cancer	0.000393	0.00264	CbGbCtD
Doxorubicin—ABCB1—Cisplatin—testicular cancer	0.000382	0.00256	CbGbCtD
Doxorubicin—ABCB1—Etoposide—testicular cancer	0.000376	0.00252	CbGbCtD
Doxorubicin—NQO1—Validated transcriptional targets of TAp63 isoforms—TFAP2C—testicular cancer	0.000372	0.0561	CbGpPWpGaD
Doxorubicin—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000351	0.0529	CbGpPWpGaD
Doxorubicin—AKR1A1—seminal vesicle—testicular cancer	0.000351	0.0233	CbGeAlD
Doxorubicin—ABCB8—gonad—testicular cancer	0.000341	0.0227	CbGeAlD
Doxorubicin—SLC22A16—testis—testicular cancer	0.000316	0.021	CbGeAlD
Doxorubicin—ABCB8—female gonad—testicular cancer	0.000277	0.0184	CbGeAlD
Doxorubicin—CBR3—female gonad—testicular cancer	0.000267	0.0178	CbGeAlD
Doxorubicin—NDUFS2—seminal vesicle—testicular cancer	0.000264	0.0176	CbGeAlD
Doxorubicin—CBR1—NRF2 pathway—SLC2A6—testicular cancer	0.000263	0.0397	CbGpPWpGaD
Doxorubicin—NDUFS3—seminal vesicle—testicular cancer	0.000261	0.0174	CbGeAlD
Doxorubicin—AKR1A1—gonad—testicular cancer	0.000253	0.0169	CbGeAlD
Doxorubicin—CYP3A4—Vinblastine—testicular cancer	0.00025	0.00168	CbGbCtD
Doxorubicin—ABCB1—Methotrexate—testicular cancer	0.000248	0.00167	CbGbCtD
Doxorubicin—DHCR7—seminal vesicle—testicular cancer	0.000248	0.0165	CbGeAlD
Doxorubicin—ABCB8—testis—testicular cancer	0.000246	0.0164	CbGeAlD
Doxorubicin—SLC22A16—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000239	0.0361	CbGpPWpGaD
Doxorubicin—CBR3—testis—testicular cancer	0.000236	0.0157	CbGeAlD
Doxorubicin—YWHAG—seminal vesicle—testicular cancer	0.000227	0.0151	CbGeAlD
Doxorubicin—CYP3A4—Etoposide—testicular cancer	0.000225	0.00151	CbGbCtD
Doxorubicin—CBR1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000225	0.0339	CbGpPWpGaD
Doxorubicin—AURKA—gonad—testicular cancer	0.000214	0.0143	CbGeAlD
Doxorubicin—AKR1A1—female gonad—testicular cancer	0.000206	0.0137	CbGeAlD
Doxorubicin—RALBP1—seminal vesicle—testicular cancer	0.000205	0.0137	CbGeAlD
Doxorubicin—ABCB8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000197	0.0297	CbGpPWpGaD
Doxorubicin—NOS1—gonad—testicular cancer	0.000192	0.0128	CbGeAlD
Doxorubicin—CBR1—seminal vesicle—testicular cancer	0.000192	0.0128	CbGeAlD
Doxorubicin—NDUFS2—gonad—testicular cancer	0.000191	0.0127	CbGeAlD
Doxorubicin—AKR1C3—seminal vesicle—testicular cancer	0.000189	0.0126	CbGeAlD
Doxorubicin—NDUFS3—gonad—testicular cancer	0.000188	0.0125	CbGeAlD
Doxorubicin—NDUFS7—female gonad—testicular cancer	0.000187	0.0125	CbGeAlD
Doxorubicin—AKR1A1—testis—testicular cancer	0.000183	0.0122	CbGeAlD
Doxorubicin—DHCR7—gonad—testicular cancer	0.000179	0.0119	CbGeAlD
Doxorubicin—ABCB8—lymph node—testicular cancer	0.000178	0.0119	CbGeAlD
Doxorubicin—AURKA—female gonad—testicular cancer	0.000174	0.0116	CbGeAlD
Doxorubicin—POR—seminal vesicle—testicular cancer	0.000173	0.0115	CbGeAlD
Doxorubicin—CBR3—lymph node—testicular cancer	0.000171	0.0114	CbGeAlD
Doxorubicin—NDUFS7—testis—testicular cancer	0.000166	0.011	CbGeAlD
Doxorubicin—YWHAG—gonad—testicular cancer	0.000164	0.0109	CbGeAlD
Doxorubicin—NDUFS2—female gonad—testicular cancer	0.000155	0.0103	CbGeAlD
Doxorubicin—AURKA—testis—testicular cancer	0.000154	0.0103	CbGeAlD
Doxorubicin—NQO1—seminal vesicle—testicular cancer	0.000154	0.0102	CbGeAlD
Doxorubicin—NQO1—NRF2 pathway—SLC2A6—testicular cancer	0.000154	0.0232	CbGpPWpGaD
Doxorubicin—NDUFS3—female gonad—testicular cancer	0.000153	0.0102	CbGeAlD
Doxorubicin—DHCR7—female gonad—testicular cancer	0.000145	0.00969	CbGeAlD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00014	0.0212	CbGpPWpGaD
Doxorubicin—CBR1—gonad—testicular cancer	0.000138	0.00922	CbGeAlD
Doxorubicin—NOS1—testis—testicular cancer	0.000138	0.00921	CbGeAlD
Doxorubicin—NDUFS2—testis—testicular cancer	0.000137	0.00915	CbGeAlD
Doxorubicin—ABCC10—seminal vesicle—testicular cancer	0.000137	0.00913	CbGeAlD
Doxorubicin—NDUFS3—testis—testicular cancer	0.000136	0.00904	CbGeAlD
Doxorubicin—YWHAG—female gonad—testicular cancer	0.000134	0.00889	CbGeAlD
Doxorubicin—AKR1A1—lymph node—testicular cancer	0.000132	0.00881	CbGeAlD
Doxorubicin—DHCR7—testis—testicular cancer	0.000129	0.00859	CbGeAlD
Doxorubicin—AKR1C3—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000127	0.0191	CbGpPWpGaD
Doxorubicin—SLC22A16—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000121	0.0183	CbGpPWpGaD
Doxorubicin—RALBP1—female gonad—testicular cancer	0.000121	0.00803	CbGeAlD
Doxorubicin—NDUFS7—lymph node—testicular cancer	0.00012	0.00801	CbGeAlD
Doxorubicin—YWHAG—testis—testicular cancer	0.000118	0.00788	CbGeAlD
Doxorubicin—ABCB11—testis—testicular cancer	0.000113	0.00751	CbGeAlD
Doxorubicin—CBR1—female gonad—testicular cancer	0.000113	0.00749	CbGeAlD
Doxorubicin—AURKA—lymph node—testicular cancer	0.000112	0.00745	CbGeAlD
Doxorubicin—AKR1C3—female gonad—testicular cancer	0.000111	0.0074	CbGeAlD
Doxorubicin—YWHAG—LKB1 signaling events—STK11—testicular cancer	0.00011	0.0167	CbGpPWpGaD
Doxorubicin—RALBP1—testis—testicular cancer	0.000107	0.00712	CbGeAlD
Doxorubicin—NOS3—testis—testicular cancer	0.000105	0.007	CbGeAlD
Doxorubicin—POR—female gonad—testicular cancer	0.000102	0.00676	CbGeAlD
Doxorubicin—CBR1—testis—testicular cancer	9.98e-05	0.00665	CbGeAlD
Doxorubicin—NDUFS2—lymph node—testicular cancer	9.97e-05	0.00664	CbGeAlD
Doxorubicin—ABCC10—gonad—testicular cancer	9.91e-05	0.0066	CbGeAlD
Doxorubicin—AKR1C3—testis—testicular cancer	9.86e-05	0.00656	CbGeAlD
Doxorubicin—NDUFS3—lymph node—testicular cancer	9.84e-05	0.00655	CbGeAlD
Doxorubicin—ABCC3—NRF2 pathway—SLC2A6—testicular cancer	9.73e-05	0.0147	CbGpPWpGaD
Doxorubicin—ABCC1—seminal vesicle—testicular cancer	9.7e-05	0.00646	CbGeAlD
Doxorubicin—TOP2A—female gonad—testicular cancer	9.46e-05	0.0063	CbGeAlD
Doxorubicin—DHCR7—lymph node—testicular cancer	9.35e-05	0.00623	CbGeAlD
Doxorubicin—ABCC6—Podofilox—Etoposide—testicular cancer	9.21e-05	0.123	CbGdCrCtD
Doxorubicin—ABCC6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.21e-05	0.0139	CbGpPWpGaD
Doxorubicin—NQO1—female gonad—testicular cancer	9.02e-05	0.006	CbGeAlD
Doxorubicin—POR—testis—testicular cancer	9e-05	0.00599	CbGeAlD
Doxorubicin—NQO1—Vincristine—Vinblastine—testicular cancer	8.62e-05	0.115	CbGdCrCtD
Doxorubicin—YWHAG—lymph node—testicular cancer	8.58e-05	0.00571	CbGeAlD
Doxorubicin—TOP2A—testis—testicular cancer	8.39e-05	0.00559	CbGeAlD
Doxorubicin—CBR3—Teniposide—Etoposide—testicular cancer	8.3e-05	0.111	CbGdCrCtD
Doxorubicin—ABCC3—female gonad—testicular cancer	8.09e-05	0.00539	CbGeAlD
Doxorubicin—AKR1C3—Podofilox—Etoposide—testicular cancer	8.05e-05	0.108	CbGdCrCtD
Doxorubicin—ABCC10—female gonad—testicular cancer	8.05e-05	0.00536	CbGeAlD
Doxorubicin—ABCC10—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.05e-05	0.0121	CbGpPWpGaD
Doxorubicin—ABCG2—seminal vesicle—testicular cancer	8.03e-05	0.00535	CbGeAlD
Doxorubicin—NQO1—testis—testicular cancer	8e-05	0.00533	CbGeAlD
Doxorubicin—YWHAG—Cell Cycle—MAD1L1—testicular cancer	7.98e-05	0.0121	CbGpPWpGaD
Doxorubicin—CYP1B1—gonad—testicular cancer	7.79e-05	0.00519	CbGeAlD
Doxorubicin—RALBP1—lymph node—testicular cancer	7.75e-05	0.00516	CbGeAlD
Doxorubicin—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	7.72e-05	0.0116	CbGpPWpGaD
Doxorubicin—NOS3—lymph node—testicular cancer	7.63e-05	0.00508	CbGeAlD
Doxorubicin—CBR1—lymph node—testicular cancer	7.24e-05	0.00482	CbGeAlD
Doxorubicin—ABCC3—testis—testicular cancer	7.18e-05	0.00478	CbGeAlD
Doxorubicin—AKR1C3—lymph node—testicular cancer	7.15e-05	0.00476	CbGeAlD
Doxorubicin—ABCC10—testis—testicular cancer	7.14e-05	0.00476	CbGeAlD
Doxorubicin—AKR1C3—Vincristine—Vinblastine—testicular cancer	6.89e-05	0.0922	CbGdCrCtD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	6.74e-05	0.0102	CbGpPWpGaD
Doxorubicin—POR—lymph node—testicular cancer	6.53e-05	0.00434	CbGeAlD
Doxorubicin—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	6.52e-05	0.00984	CbGpPWpGaD
Doxorubicin—CYP1B1—female gonad—testicular cancer	6.33e-05	0.00422	CbGeAlD
Doxorubicin—CYP1B1—Arachidonic acid metabolism—HPGDS—testicular cancer	6.31e-05	0.00952	CbGpPWpGaD
Doxorubicin—TOP2A—lymph node—testicular cancer	6.08e-05	0.00405	CbGeAlD
Doxorubicin—NQO1—lymph node—testicular cancer	5.8e-05	0.00386	CbGeAlD
Doxorubicin—ABCC2—testis—testicular cancer	5.74e-05	0.00382	CbGeAlD
Doxorubicin—ABCC1—female gonad—testicular cancer	5.7e-05	0.00379	CbGeAlD
Doxorubicin—CYP1B1—testis—testicular cancer	5.62e-05	0.00374	CbGeAlD
Doxorubicin—NOS3—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—testicular cancer	5.54e-05	0.00836	CbGpPWpGaD
Doxorubicin—CYP2B6—gonad—testicular cancer	5.35e-05	0.00356	CbGeAlD
Doxorubicin—AURKA—Integrated Breast Cancer Pathway—STK11—testicular cancer	5.34e-05	0.00805	CbGpPWpGaD
Doxorubicin—CBR1—Vincristine—Vinblastine—testicular cancer	5.26e-05	0.0704	CbGdCrCtD
Doxorubicin—ABCC3—lymph node—testicular cancer	5.2e-05	0.00346	CbGeAlD
Doxorubicin—ABCC10—lymph node—testicular cancer	5.18e-05	0.00345	CbGeAlD
Doxorubicin—YWHAG—Cell Cycle—KITLG—testicular cancer	5.12e-05	0.00773	CbGpPWpGaD
Doxorubicin—NOS3—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	5.1e-05	0.0077	CbGpPWpGaD
Doxorubicin—ABCC1—testis—testicular cancer	5.05e-05	0.00336	CbGeAlD
Doxorubicin—NOS2—ATF-2 transcription factor network—MMP2—testicular cancer	4.91e-05	0.00741	CbGpPWpGaD
Doxorubicin—ABCG2—female gonad—testicular cancer	4.72e-05	0.00314	CbGeAlD
Doxorubicin—NOS2—AGE/RAGE pathway—MMP2—testicular cancer	4.49e-05	0.00677	CbGpPWpGaD
Doxorubicin—TOP2A—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	4.42e-05	0.00667	CbGpPWpGaD
Doxorubicin—AURKA—Teniposide—Etoposide—testicular cancer	4.37e-05	0.0585	CbGdCrCtD
Doxorubicin—NOS3—Angiopoietin receptor Tie2-mediated signaling—MMP2—testicular cancer	4.35e-05	0.00657	CbGpPWpGaD
Doxorubicin—CBR3—Idarubicin—Epirubicin—testicular cancer	4.33e-05	0.0579	CbGdCrCtD
Doxorubicin—CBR3—Daunorubicin—Epirubicin—testicular cancer	4.33e-05	0.0579	CbGdCrCtD
Doxorubicin—ABCB1—embryo—testicular cancer	4.22e-05	0.00281	CbGeAlD
Doxorubicin—ABCG2—testis—testicular cancer	4.18e-05	0.00278	CbGeAlD
Doxorubicin—ABCC2—lymph node—testicular cancer	4.16e-05	0.00277	CbGeAlD
Doxorubicin—CYP1B1—lymph node—testicular cancer	4.07e-05	0.00271	CbGeAlD
Doxorubicin—ABCB1—seminal vesicle—testicular cancer	3.96e-05	0.00264	CbGeAlD
Doxorubicin—CYP2B6—testis—testicular cancer	3.86e-05	0.00257	CbGeAlD
Doxorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	3.76e-05	0.00568	CbGpPWpGaD
Doxorubicin—ABCC1—lymph node—testicular cancer	3.66e-05	0.00244	CbGeAlD
Doxorubicin—NOS3—AGE/RAGE pathway—MMP2—testicular cancer	3.48e-05	0.00526	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.45e-05	0.0052	CbGpPWpGaD
Doxorubicin—CYP2D6—female gonad—testicular cancer	3.23e-05	0.00215	CbGeAlD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	3.23e-05	0.00487	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.21e-05	0.00485	CbGpPWpGaD
Doxorubicin—ABCC3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.12e-05	0.0047	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle, Mitotic—MAD1L1—testicular cancer	3.09e-05	0.00466	CbGpPWpGaD
Doxorubicin—ABCG2—lymph node—testicular cancer	3.03e-05	0.00202	CbGeAlD
Doxorubicin—CYP2D6—testis—testicular cancer	2.87e-05	0.00191	CbGeAlD
Doxorubicin—ABCB1—gonad—testicular cancer	2.86e-05	0.00191	CbGeAlD
Doxorubicin—RALBP1—Signaling Pathways—INSL3—testicular cancer	2.78e-05	0.00419	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—MAD1L1—testicular cancer	2.76e-05	0.00417	CbGpPWpGaD
Doxorubicin—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	2.68e-05	0.00404	CbGpPWpGaD
Doxorubicin—TOP2A—Vindesine—Vinblastine—testicular cancer	2.65e-05	0.0354	CbGdCrCtD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.47e-05	0.00373	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.44e-05	0.00369	CbGpPWpGaD
Doxorubicin—CYP1B1—Biological oxidations—HPGDS—testicular cancer	2.35e-05	0.00354	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.34e-05	0.00354	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—MAD1L1—testicular cancer	2.34e-05	0.00353	CbGpPWpGaD
Doxorubicin—ABCB1—female gonad—testicular cancer	2.33e-05	0.00155	CbGeAlD
Doxorubicin—AURKA—Daunorubicin—Epirubicin—testicular cancer	2.28e-05	0.0305	CbGdCrCtD
Doxorubicin—AURKA—Idarubicin—Epirubicin—testicular cancer	2.28e-05	0.0305	CbGdCrCtD
Doxorubicin—AURKA—Cell Cycle, Mitotic—H2AFZ—testicular cancer	2.15e-05	0.00325	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.15e-05	0.00324	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—MAD1L1—testicular cancer	2.09e-05	0.00316	CbGpPWpGaD
Doxorubicin—ABCB1—testis—testicular cancer	2.06e-05	0.00137	CbGeAlD
Doxorubicin—AURKA—Cell Cycle—H2AFZ—testicular cancer	1.92e-05	0.0029	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—HPGDS—testicular cancer	1.92e-05	0.0029	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—HPGDS—testicular cancer	1.92e-05	0.0029	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.81e-05	0.00273	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—HPGDS—testicular cancer	1.81e-05	0.00272	CbGpPWpGaD
Doxorubicin—TOP2A—Vinorelbine—Vinblastine—testicular cancer	1.67e-05	0.0224	CbGdCrCtD
Doxorubicin—TOP2A—Teniposide—Etoposide—testicular cancer	1.67e-05	0.0223	CbGdCrCtD
Doxorubicin—TOP2A—Podofilox—Etoposide—testicular cancer	1.67e-05	0.0223	CbGdCrCtD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—MAD1L1—testicular cancer	1.64e-05	0.00247	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—H2AFZ—testicular cancer	1.63e-05	0.00246	CbGpPWpGaD
Doxorubicin—CYP2B6—Biological oxidations—HPGDS—testicular cancer	1.57e-05	0.00236	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—INSL3—testicular cancer	1.54e-05	0.00232	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—HPGDS—testicular cancer	1.53e-05	0.00232	CbGpPWpGaD
Doxorubicin—ABCB1—lymph node—testicular cancer	1.49e-05	0.000995	CbGeAlD
Doxorubicin—TOP2A—Cell Cycle—MAD1L1—testicular cancer	1.46e-05	0.00221	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—H2AFZ—testicular cancer	1.46e-05	0.0022	CbGpPWpGaD
Doxorubicin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	1.45e-05	0.00218	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—HPGDS—testicular cancer	1.43e-05	0.00216	CbGpPWpGaD
Doxorubicin—TOP2A—Vincristine—Vinblastine—testicular cancer	1.43e-05	0.0191	CbGdCrCtD
Doxorubicin—NDUFS3—Metabolism—STK11—testicular cancer	1.4e-05	0.00211	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—STK11—testicular cancer	1.4e-05	0.00211	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—STK11—testicular cancer	1.31e-05	0.00198	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—INSL3—testicular cancer	1.3e-05	0.00196	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.24e-05	0.00187	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.19e-05	0.0018	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.16e-05	0.00175	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—H2AFZ—testicular cancer	1.14e-05	0.00172	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—STK11—testicular cancer	1.12e-05	0.00168	CbGpPWpGaD
Doxorubicin—CYP2D6—Biological oxidations—HPGDS—testicular cancer	1.09e-05	0.00164	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.06e-05	0.0016	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—STK11—testicular cancer	1.04e-05	0.00157	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—H2AFZ—testicular cancer	1.02e-05	0.00154	CbGpPWpGaD
Doxorubicin—NOS1—Disease—H2AFZ—testicular cancer	1.02e-05	0.00153	CbGpPWpGaD
Doxorubicin—NOS1—Disease—KITLG—testicular cancer	9.34e-06	0.00141	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.32e-06	0.00141	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.02e-06	0.00136	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—H2AFZ—testicular cancer	8.89e-06	0.00134	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—STK11—testicular cancer	8.84e-06	0.00133	CbGpPWpGaD
Doxorubicin—TOP2A—Idarubicin—Epirubicin—testicular cancer	8.71e-06	0.0117	CbGdCrCtD
Doxorubicin—TOP2A—Daunorubicin—Epirubicin—testicular cancer	8.71e-06	0.0117	CbGdCrCtD
Doxorubicin—NQO1—Metabolism—HPGDS—testicular cancer	8.36e-06	0.00126	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—KITLG—testicular cancer	8.18e-06	0.00123	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—HPGDS—testicular cancer	8.06e-06	0.00122	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	7.72e-06	0.00116	CbGpPWpGaD
Doxorubicin—NOS2—Disease—H2AFZ—testicular cancer	7.66e-06	0.00116	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—HPGDS—testicular cancer	7.5e-06	0.00113	CbGpPWpGaD
Doxorubicin—Bronchitis—Epirubicin—testicular cancer	7.37e-06	0.000177	CcSEcCtD
Doxorubicin—Diarrhoea—Dactinomycin—testicular cancer	7.35e-06	0.000176	CcSEcCtD
Doxorubicin—Pneumonia—Methotrexate—testicular cancer	7.34e-06	0.000176	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Cisplatin—testicular cancer	7.33e-06	0.000176	CcSEcCtD
Doxorubicin—Vomiting—Bleomycin—testicular cancer	7.32e-06	0.000176	CcSEcCtD
Doxorubicin—Drowsiness—Methotrexate—testicular cancer	7.3e-06	0.000175	CcSEcCtD
Doxorubicin—Infestation—Methotrexate—testicular cancer	7.3e-06	0.000175	CcSEcCtD
Doxorubicin—Infestation NOS—Methotrexate—testicular cancer	7.3e-06	0.000175	CcSEcCtD
Doxorubicin—Pancytopenia—Epirubicin—testicular cancer	7.28e-06	0.000175	CcSEcCtD
Doxorubicin—Hypotension—Etoposide—testicular cancer	7.26e-06	0.000174	CcSEcCtD
Doxorubicin—Rash—Bleomycin—testicular cancer	7.26e-06	0.000174	CcSEcCtD
Doxorubicin—Pain—Cisplatin—testicular cancer	7.26e-06	0.000174	CcSEcCtD
Doxorubicin—Dermatitis—Bleomycin—testicular cancer	7.26e-06	0.000174	CcSEcCtD
Doxorubicin—Hypersensitivity—Ifosfamide—testicular cancer	7.25e-06	0.000174	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Methotrexate—testicular cancer	7.24e-06	0.000174	CcSEcCtD
Doxorubicin—Renal failure—Methotrexate—testicular cancer	7.18e-06	0.000172	CcSEcCtD
Doxorubicin—Neutropenia—Epirubicin—testicular cancer	7.17e-06	0.000172	CcSEcCtD
Doxorubicin—Dysuria—Epirubicin—testicular cancer	7.17e-06	0.000172	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Epirubicin—testicular cancer	7.12e-06	0.000171	CcSEcCtD
Doxorubicin—Stomatitis—Methotrexate—testicular cancer	7.12e-06	0.000171	CcSEcCtD
Doxorubicin—CYP3A4—Biological oxidations—HPGDS—testicular cancer	7.12e-06	0.00107	CbGpPWpGaD
Doxorubicin—Conjunctivitis—Methotrexate—testicular cancer	7.1e-06	0.00017	CcSEcCtD
Doxorubicin—Pollakiuria—Epirubicin—testicular cancer	7.08e-06	0.00017	CcSEcCtD
Doxorubicin—Asthenia—Ifosfamide—testicular cancer	7.06e-06	0.00017	CcSEcCtD
Doxorubicin—NOS2—Disease—KITLG—testicular cancer	7.04e-06	0.00106	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—H2AFZ—testicular cancer	7.04e-06	0.00106	CbGpPWpGaD
Doxorubicin—Sweating—Methotrexate—testicular cancer	7e-06	0.000168	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Epirubicin—testicular cancer	6.99e-06	0.000168	CcSEcCtD
Doxorubicin—Feeling abnormal—Cisplatin—testicular cancer	6.99e-06	0.000168	CcSEcCtD
Doxorubicin—Paraesthesia—Etoposide—testicular cancer	6.98e-06	0.000168	CcSEcCtD
Doxorubicin—Weight increased—Epirubicin—testicular cancer	6.97e-06	0.000167	CcSEcCtD
Doxorubicin—Pruritus—Ifosfamide—testicular cancer	6.96e-06	0.000167	CcSEcCtD
Doxorubicin—Haematuria—Methotrexate—testicular cancer	6.96e-06	0.000167	CcSEcCtD
Doxorubicin—NOS1—Disease—FGFR3—testicular cancer	6.94e-06	0.00105	CbGpPWpGaD
Doxorubicin—Weight decreased—Epirubicin—testicular cancer	6.93e-06	0.000166	CcSEcCtD
Doxorubicin—Dyspnoea—Etoposide—testicular cancer	6.93e-06	0.000166	CcSEcCtD
Doxorubicin—Hyperglycaemia—Epirubicin—testicular cancer	6.91e-06	0.000166	CcSEcCtD
Doxorubicin—Somnolence—Etoposide—testicular cancer	6.91e-06	0.000166	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Methotrexate—testicular cancer	6.91e-06	0.000166	CcSEcCtD
Doxorubicin—Epistaxis—Methotrexate—testicular cancer	6.89e-06	0.000165	CcSEcCtD
Doxorubicin—Pneumonia—Epirubicin—testicular cancer	6.87e-06	0.000165	CcSEcCtD
Doxorubicin—Nausea—Bleomycin—testicular cancer	6.84e-06	0.000164	CcSEcCtD
Doxorubicin—Infestation—Epirubicin—testicular cancer	6.83e-06	0.000164	CcSEcCtD
Doxorubicin—Drowsiness—Epirubicin—testicular cancer	6.83e-06	0.000164	CcSEcCtD
Doxorubicin—Infestation NOS—Epirubicin—testicular cancer	6.83e-06	0.000164	CcSEcCtD
Doxorubicin—Vomiting—Dactinomycin—testicular cancer	6.83e-06	0.000164	CcSEcCtD
Doxorubicin—Agranulocytosis—Methotrexate—testicular cancer	6.81e-06	0.000164	CcSEcCtD
Doxorubicin—NOS3—Metabolism—HPGDS—testicular cancer	6.81e-06	0.00103	CbGpPWpGaD
Doxorubicin—Stevens-Johnson syndrome—Epirubicin—testicular cancer	6.77e-06	0.000163	CcSEcCtD
Doxorubicin—Rash—Dactinomycin—testicular cancer	6.77e-06	0.000163	CcSEcCtD
Doxorubicin—Decreased appetite—Etoposide—testicular cancer	6.76e-06	0.000162	CcSEcCtD
Doxorubicin—Diarrhoea—Ifosfamide—testicular cancer	6.73e-06	0.000162	CcSEcCtD
Doxorubicin—Renal failure—Epirubicin—testicular cancer	6.72e-06	0.000161	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Etoposide—testicular cancer	6.71e-06	0.000161	CcSEcCtD
Doxorubicin—Body temperature increased—Cisplatin—testicular cancer	6.71e-06	0.000161	CcSEcCtD
Doxorubicin—Fatigue—Etoposide—testicular cancer	6.7e-06	0.000161	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Epirubicin—testicular cancer	6.7e-06	0.000161	CcSEcCtD
Doxorubicin—Jaundice—Epirubicin—testicular cancer	6.66e-06	0.00016	CcSEcCtD
Doxorubicin—Stomatitis—Epirubicin—testicular cancer	6.66e-06	0.00016	CcSEcCtD
Doxorubicin—Constipation—Etoposide—testicular cancer	6.65e-06	0.00016	CcSEcCtD
Doxorubicin—Pain—Etoposide—testicular cancer	6.65e-06	0.00016	CcSEcCtD
Doxorubicin—Urinary tract infection—Epirubicin—testicular cancer	6.64e-06	0.000159	CcSEcCtD
Doxorubicin—Conjunctivitis—Epirubicin—testicular cancer	6.64e-06	0.000159	CcSEcCtD
Doxorubicin—Haemoglobin—Methotrexate—testicular cancer	6.59e-06	0.000158	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—testicular cancer	6.55e-06	0.000157	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—testicular cancer	6.55e-06	0.000157	CcSEcCtD
Doxorubicin—Sweating—Epirubicin—testicular cancer	6.55e-06	0.000157	CcSEcCtD
Doxorubicin—Haematuria—Epirubicin—testicular cancer	6.51e-06	0.000156	CcSEcCtD
Doxorubicin—Dizziness—Ifosfamide—testicular cancer	6.51e-06	0.000156	CcSEcCtD
Doxorubicin—Pharyngitis—Methotrexate—testicular cancer	6.51e-06	0.000156	CcSEcCtD
Doxorubicin—Urinary tract disorder—Methotrexate—testicular cancer	6.47e-06	0.000155	CcSEcCtD
Doxorubicin—AKR1C3—Disease—KITLG—testicular cancer	6.47e-06	0.000977	CbGpPWpGaD
Doxorubicin—Hepatobiliary disease—Epirubicin—testicular cancer	6.46e-06	0.000155	CcSEcCtD
Doxorubicin—Epistaxis—Epirubicin—testicular cancer	6.44e-06	0.000155	CcSEcCtD
Doxorubicin—Urethral disorder—Methotrexate—testicular cancer	6.43e-06	0.000154	CcSEcCtD
Doxorubicin—Sinusitis—Epirubicin—testicular cancer	6.41e-06	0.000154	CcSEcCtD
Doxorubicin—Feeling abnormal—Etoposide—testicular cancer	6.41e-06	0.000154	CcSEcCtD
Doxorubicin—Nausea—Dactinomycin—testicular cancer	6.38e-06	0.000153	CcSEcCtD
Doxorubicin—Agranulocytosis—Epirubicin—testicular cancer	6.38e-06	0.000153	CcSEcCtD
Doxorubicin—NOS1—Disease—KIT—testicular cancer	6.37e-06	0.000962	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Etoposide—testicular cancer	6.36e-06	0.000153	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—testicular cancer	6.32e-06	0.000152	CcSEcCtD
Doxorubicin—Vomiting—Ifosfamide—testicular cancer	6.26e-06	0.00015	CcSEcCtD
Doxorubicin—Hypersensitivity—Cisplatin—testicular cancer	6.25e-06	0.00015	CcSEcCtD
Doxorubicin—Bradycardia—Epirubicin—testicular cancer	6.24e-06	0.00015	CcSEcCtD
Doxorubicin—Rash—Ifosfamide—testicular cancer	6.21e-06	0.000149	CcSEcCtD
Doxorubicin—Dermatitis—Ifosfamide—testicular cancer	6.2e-06	0.000149	CcSEcCtD
Doxorubicin—Erythema multiforme—Methotrexate—testicular cancer	6.2e-06	0.000149	CcSEcCtD
Doxorubicin—Urticaria—Etoposide—testicular cancer	6.18e-06	0.000148	CcSEcCtD
Doxorubicin—Haemoglobin—Epirubicin—testicular cancer	6.17e-06	0.000148	CcSEcCtD
Doxorubicin—Rhinitis—Epirubicin—testicular cancer	6.15e-06	0.000148	CcSEcCtD
Doxorubicin—Body temperature increased—Etoposide—testicular cancer	6.15e-06	0.000148	CcSEcCtD
Doxorubicin—Abdominal pain—Etoposide—testicular cancer	6.15e-06	0.000148	CcSEcCtD
Doxorubicin—Haemorrhage—Epirubicin—testicular cancer	6.13e-06	0.000147	CcSEcCtD
Doxorubicin—Hepatitis—Epirubicin—testicular cancer	6.13e-06	0.000147	CcSEcCtD
Doxorubicin—Eye disorder—Methotrexate—testicular cancer	6.13e-06	0.000147	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—testicular cancer	6.11e-06	0.000147	CcSEcCtD
Doxorubicin—Hypoaesthesia—Epirubicin—testicular cancer	6.1e-06	0.000147	CcSEcCtD
Doxorubicin—Asthenia—Cisplatin—testicular cancer	6.09e-06	0.000146	CcSEcCtD
Doxorubicin—Pharyngitis—Epirubicin—testicular cancer	6.09e-06	0.000146	CcSEcCtD
Doxorubicin—Cardiac disorder—Methotrexate—testicular cancer	6.08e-06	0.000146	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—FGFR3—testicular cancer	6.08e-06	0.000917	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—STK11—testicular cancer	6.07e-06	0.000916	CbGpPWpGaD
Doxorubicin—Urinary tract disorder—Epirubicin—testicular cancer	6.06e-06	0.000145	CcSEcCtD
Doxorubicin—Oedema peripheral—Epirubicin—testicular cancer	6.04e-06	0.000145	CcSEcCtD
Doxorubicin—Connective tissue disorder—Epirubicin—testicular cancer	6.03e-06	0.000145	CcSEcCtD
Doxorubicin—Urethral disorder—Epirubicin—testicular cancer	6.01e-06	0.000144	CcSEcCtD
Doxorubicin—Angiopathy—Methotrexate—testicular cancer	5.95e-06	0.000143	CcSEcCtD
Doxorubicin—NOS3—Disease—H2AFZ—testicular cancer	5.95e-06	0.000897	CbGpPWpGaD
Doxorubicin—Immune system disorder—Methotrexate—testicular cancer	5.92e-06	0.000142	CcSEcCtD
Doxorubicin—Visual impairment—Epirubicin—testicular cancer	5.91e-06	0.000142	CcSEcCtD
Doxorubicin—Mediastinal disorder—Methotrexate—testicular cancer	5.91e-06	0.000142	CcSEcCtD
Doxorubicin—Chills—Methotrexate—testicular cancer	5.88e-06	0.000141	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism—STK11—testicular cancer	5.86e-06	0.000884	CbGpPWpGaD
Doxorubicin—Nausea—Ifosfamide—testicular cancer	5.85e-06	0.00014	CcSEcCtD
Doxorubicin—Diarrhoea—Cisplatin—testicular cancer	5.81e-06	0.000139	CcSEcCtD
Doxorubicin—Erythema multiforme—Epirubicin—testicular cancer	5.8e-06	0.000139	CcSEcCtD
Doxorubicin—Alopecia—Methotrexate—testicular cancer	5.79e-06	0.000139	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—testicular cancer	5.74e-06	0.000138	CcSEcCtD
Doxorubicin—Eye disorder—Epirubicin—testicular cancer	5.73e-06	0.000138	CcSEcCtD
Doxorubicin—Hypersensitivity—Etoposide—testicular cancer	5.73e-06	0.000138	CcSEcCtD
Doxorubicin—Tinnitus—Epirubicin—testicular cancer	5.72e-06	0.000137	CcSEcCtD
Doxorubicin—Malnutrition—Methotrexate—testicular cancer	5.71e-06	0.000137	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—testicular cancer	5.71e-06	0.000137	CcSEcCtD
Doxorubicin—Flushing—Epirubicin—testicular cancer	5.69e-06	0.000137	CcSEcCtD
Doxorubicin—Cardiac disorder—Epirubicin—testicular cancer	5.69e-06	0.000137	CcSEcCtD
Doxorubicin—Dysgeusia—Methotrexate—testicular cancer	5.59e-06	0.000134	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—KIT—testicular cancer	5.58e-06	0.000842	CbGpPWpGaD
Doxorubicin—Asthenia—Etoposide—testicular cancer	5.58e-06	0.000134	CcSEcCtD
Doxorubicin—Angiopathy—Epirubicin—testicular cancer	5.57e-06	0.000134	CcSEcCtD
Doxorubicin—Immune system disorder—Epirubicin—testicular cancer	5.54e-06	0.000133	CcSEcCtD
Doxorubicin—Mediastinal disorder—Epirubicin—testicular cancer	5.53e-06	0.000133	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—HPGDS—testicular cancer	5.53e-06	0.000834	CbGpPWpGaD
Doxorubicin—Back pain—Methotrexate—testicular cancer	5.52e-06	0.000133	CcSEcCtD
Doxorubicin—Chills—Epirubicin—testicular cancer	5.5e-06	0.000132	CcSEcCtD
Doxorubicin—Pruritus—Etoposide—testicular cancer	5.5e-06	0.000132	CcSEcCtD
Doxorubicin—Arrhythmia—Epirubicin—testicular cancer	5.48e-06	0.000132	CcSEcCtD
Doxorubicin—NOS3—Disease—KITLG—testicular cancer	5.47e-06	0.000825	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—STK11—testicular cancer	5.45e-06	0.000822	CbGpPWpGaD
Doxorubicin—Alopecia—Epirubicin—testicular cancer	5.42e-06	0.00013	CcSEcCtD
Doxorubicin—Vomiting—Cisplatin—testicular cancer	5.4e-06	0.00013	CcSEcCtD
Doxorubicin—Vision blurred—Methotrexate—testicular cancer	5.38e-06	0.000129	CcSEcCtD
Doxorubicin—Mental disorder—Epirubicin—testicular cancer	5.37e-06	0.000129	CcSEcCtD
Doxorubicin—Rash—Cisplatin—testicular cancer	5.35e-06	0.000128	CcSEcCtD
Doxorubicin—Dermatitis—Cisplatin—testicular cancer	5.35e-06	0.000128	CcSEcCtD
Doxorubicin—Malnutrition—Epirubicin—testicular cancer	5.34e-06	0.000128	CcSEcCtD
Doxorubicin—Erythema—Epirubicin—testicular cancer	5.34e-06	0.000128	CcSEcCtD
Doxorubicin—Diarrhoea—Etoposide—testicular cancer	5.32e-06	0.000128	CcSEcCtD
Doxorubicin—ABCC3—Metabolism—HPGDS—testicular cancer	5.3e-06	0.0008	CbGpPWpGaD
Doxorubicin—Ill-defined disorder—Methotrexate—testicular cancer	5.29e-06	0.000127	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—testicular cancer	5.27e-06	0.000127	CcSEcCtD
Doxorubicin—Flatulence—Epirubicin—testicular cancer	5.26e-06	0.000126	CcSEcCtD
Doxorubicin—Tension—Epirubicin—testicular cancer	5.24e-06	0.000126	CcSEcCtD
Doxorubicin—NOS2—Disease—FGFR3—testicular cancer	5.24e-06	0.00079	CbGpPWpGaD
Doxorubicin—Dysgeusia—Epirubicin—testicular cancer	5.23e-06	0.000126	CcSEcCtD
Doxorubicin—Nervousness—Epirubicin—testicular cancer	5.19e-06	0.000125	CcSEcCtD
Doxorubicin—Back pain—Epirubicin—testicular cancer	5.17e-06	0.000124	CcSEcCtD
Doxorubicin—Malaise—Methotrexate—testicular cancer	5.15e-06	0.000124	CcSEcCtD
Doxorubicin—Dizziness—Etoposide—testicular cancer	5.14e-06	0.000123	CcSEcCtD
Doxorubicin—Muscle spasms—Epirubicin—testicular cancer	5.13e-06	0.000123	CcSEcCtD
Doxorubicin—Vertigo—Methotrexate—testicular cancer	5.13e-06	0.000123	CcSEcCtD
Doxorubicin—Leukopenia—Methotrexate—testicular cancer	5.11e-06	0.000123	CcSEcCtD
Doxorubicin—Nausea—Cisplatin—testicular cancer	5.04e-06	0.000121	CcSEcCtD
Doxorubicin—Vision blurred—Epirubicin—testicular cancer	5.03e-06	0.000121	CcSEcCtD
Doxorubicin—Cough—Methotrexate—testicular cancer	4.98e-06	0.00012	CcSEcCtD
Doxorubicin—Ill-defined disorder—Epirubicin—testicular cancer	4.95e-06	0.000119	CcSEcCtD
Doxorubicin—NOS3—Metabolism—STK11—testicular cancer	4.95e-06	0.000747	CbGpPWpGaD
Doxorubicin—Convulsion—Methotrexate—testicular cancer	4.94e-06	0.000119	CcSEcCtD
Doxorubicin—Vomiting—Etoposide—testicular cancer	4.94e-06	0.000119	CcSEcCtD
Doxorubicin—Anaemia—Epirubicin—testicular cancer	4.94e-06	0.000118	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—H2AFZ—testicular cancer	4.93e-06	0.000744	CbGpPWpGaD
Doxorubicin—Agitation—Epirubicin—testicular cancer	4.91e-06	0.000118	CcSEcCtD
Doxorubicin—Rash—Etoposide—testicular cancer	4.9e-06	0.000118	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—STK11—testicular cancer	4.9e-06	0.000739	CbGpPWpGaD
Doxorubicin—Dermatitis—Etoposide—testicular cancer	4.9e-06	0.000118	CcSEcCtD
Doxorubicin—Headache—Etoposide—testicular cancer	4.87e-06	0.000117	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—testicular cancer	4.86e-06	0.000117	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—testicular cancer	4.86e-06	0.000117	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—testicular cancer	4.86e-06	0.000117	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	4.82e-06	0.000116	CcSEcCtD
Doxorubicin—Malaise—Epirubicin—testicular cancer	4.82e-06	0.000116	CcSEcCtD
Doxorubicin—AKR1C3—Disease—FGFR3—testicular cancer	4.81e-06	0.000726	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KIT—testicular cancer	4.81e-06	0.000725	CbGpPWpGaD
Doxorubicin—Discomfort—Methotrexate—testicular cancer	4.8e-06	0.000115	CcSEcCtD
Doxorubicin—Vertigo—Epirubicin—testicular cancer	4.8e-06	0.000115	CcSEcCtD
Doxorubicin—Syncope—Epirubicin—testicular cancer	4.79e-06	0.000115	CcSEcCtD
Doxorubicin—Leukopenia—Epirubicin—testicular cancer	4.78e-06	0.000115	CcSEcCtD
Doxorubicin—Palpitations—Epirubicin—testicular cancer	4.72e-06	0.000113	CcSEcCtD
Doxorubicin—Confusional state—Methotrexate—testicular cancer	4.7e-06	0.000113	CcSEcCtD
Doxorubicin—Loss of consciousness—Epirubicin—testicular cancer	4.69e-06	0.000113	CcSEcCtD
Doxorubicin—Cough—Epirubicin—testicular cancer	4.66e-06	0.000112	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—testicular cancer	4.66e-06	0.000112	CcSEcCtD
Doxorubicin—Convulsion—Epirubicin—testicular cancer	4.63e-06	0.000111	CcSEcCtD
Doxorubicin—Infection—Methotrexate—testicular cancer	4.63e-06	0.000111	CcSEcCtD
Doxorubicin—Nausea—Etoposide—testicular cancer	4.62e-06	0.000111	CcSEcCtD
Doxorubicin—Hypertension—Epirubicin—testicular cancer	4.61e-06	0.000111	CcSEcCtD
Doxorubicin—Nervous system disorder—Methotrexate—testicular cancer	4.57e-06	0.00011	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—testicular cancer	4.56e-06	0.000109	CcSEcCtD
Doxorubicin—Chest pain—Epirubicin—testicular cancer	4.55e-06	0.000109	CcSEcCtD
Doxorubicin—Myalgia—Epirubicin—testicular cancer	4.55e-06	0.000109	CcSEcCtD
Doxorubicin—Arthralgia—Epirubicin—testicular cancer	4.55e-06	0.000109	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—KITLG—testicular cancer	4.53e-06	0.000684	CbGpPWpGaD
Doxorubicin—Anxiety—Epirubicin—testicular cancer	4.53e-06	0.000109	CcSEcCtD
Doxorubicin—Skin disorder—Methotrexate—testicular cancer	4.52e-06	0.000109	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	4.51e-06	0.000108	CcSEcCtD
Doxorubicin—Hyperhidrosis—Methotrexate—testicular cancer	4.5e-06	0.000108	CcSEcCtD
Doxorubicin—Discomfort—Epirubicin—testicular cancer	4.49e-06	0.000108	CcSEcCtD
Doxorubicin—Dry mouth—Epirubicin—testicular cancer	4.45e-06	0.000107	CcSEcCtD
Doxorubicin—Anorexia—Methotrexate—testicular cancer	4.44e-06	0.000107	CcSEcCtD
Doxorubicin—AKR1C3—Disease—KIT—testicular cancer	4.42e-06	0.000667	CbGpPWpGaD
Doxorubicin—Confusional state—Epirubicin—testicular cancer	4.39e-06	0.000105	CcSEcCtD
Doxorubicin—Anaphylactic shock—Epirubicin—testicular cancer	4.36e-06	0.000105	CcSEcCtD
Doxorubicin—Oedema—Epirubicin—testicular cancer	4.36e-06	0.000105	CcSEcCtD
Doxorubicin—Hypotension—Methotrexate—testicular cancer	4.35e-06	0.000104	CcSEcCtD
Doxorubicin—Infection—Epirubicin—testicular cancer	4.33e-06	0.000104	CcSEcCtD
Doxorubicin—Shock—Epirubicin—testicular cancer	4.29e-06	0.000103	CcSEcCtD
Doxorubicin—Nervous system disorder—Epirubicin—testicular cancer	4.27e-06	0.000103	CcSEcCtD
Doxorubicin—Thrombocytopenia—Epirubicin—testicular cancer	4.27e-06	0.000102	CcSEcCtD
Doxorubicin—Tachycardia—Epirubicin—testicular cancer	4.25e-06	0.000102	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—testicular cancer	4.24e-06	0.000102	CcSEcCtD
Doxorubicin—Skin disorder—Epirubicin—testicular cancer	4.23e-06	0.000102	CcSEcCtD
Doxorubicin—Hyperhidrosis—Epirubicin—testicular cancer	4.21e-06	0.000101	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—testicular cancer	4.21e-06	0.000101	CcSEcCtD
Doxorubicin—Paraesthesia—Methotrexate—testicular cancer	4.18e-06	0.0001	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—H2AFZ—testicular cancer	4.16e-06	0.000628	CbGpPWpGaD
Doxorubicin—Anorexia—Epirubicin—testicular cancer	4.15e-06	9.97e-05	CcSEcCtD
Doxorubicin—Dyspnoea—Methotrexate—testicular cancer	4.15e-06	9.97e-05	CcSEcCtD
Doxorubicin—ABCC1—Metabolism—HPGDS—testicular cancer	4.15e-06	0.000627	CbGpPWpGaD
Doxorubicin—Somnolence—Methotrexate—testicular cancer	4.14e-06	9.94e-05	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—STK11—testicular cancer	4.14e-06	0.000625	CbGpPWpGaD
Doxorubicin—Dyspepsia—Methotrexate—testicular cancer	4.1e-06	9.84e-05	CcSEcCtD
Doxorubicin—Hypotension—Epirubicin—testicular cancer	4.07e-06	9.78e-05	CcSEcCtD
Doxorubicin—NOS3—Disease—FGFR3—testicular cancer	4.06e-06	0.000613	CbGpPWpGaD
Doxorubicin—Decreased appetite—Methotrexate—testicular cancer	4.05e-06	9.72e-05	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Methotrexate—testicular cancer	4.02e-06	9.65e-05	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—STK11—testicular cancer	4.02e-06	0.000606	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—HPGDS—testicular cancer	4.02e-06	0.000606	CbGpPWpGaD
Doxorubicin—Fatigue—Methotrexate—testicular cancer	4.01e-06	9.64e-05	CcSEcCtD
Doxorubicin—Pain—Methotrexate—testicular cancer	3.98e-06	9.56e-05	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Epirubicin—testicular cancer	3.97e-06	9.53e-05	CcSEcCtD
Doxorubicin—Insomnia—Epirubicin—testicular cancer	3.94e-06	9.46e-05	CcSEcCtD
Doxorubicin—Paraesthesia—Epirubicin—testicular cancer	3.91e-06	9.39e-05	CcSEcCtD
Doxorubicin—Dyspnoea—Epirubicin—testicular cancer	3.89e-06	9.33e-05	CcSEcCtD
Doxorubicin—Somnolence—Epirubicin—testicular cancer	3.87e-06	9.3e-05	CcSEcCtD
Doxorubicin—ABCC3—Metabolism—STK11—testicular cancer	3.85e-06	0.000581	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Methotrexate—testicular cancer	3.84e-06	9.21e-05	CcSEcCtD
Doxorubicin—Dyspepsia—Epirubicin—testicular cancer	3.84e-06	9.21e-05	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—KITLG—testicular cancer	3.83e-06	0.000578	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Methotrexate—testicular cancer	3.81e-06	9.14e-05	CcSEcCtD
Doxorubicin—Decreased appetite—Epirubicin—testicular cancer	3.79e-06	9.1e-05	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Epirubicin—testicular cancer	3.76e-06	9.03e-05	CcSEcCtD
Doxorubicin—Fatigue—Epirubicin—testicular cancer	3.76e-06	9.02e-05	CcSEcCtD
Doxorubicin—NOS3—Disease—KIT—testicular cancer	3.73e-06	0.000563	CbGpPWpGaD
Doxorubicin—Constipation—Epirubicin—testicular cancer	3.73e-06	8.95e-05	CcSEcCtD
Doxorubicin—Pain—Epirubicin—testicular cancer	3.73e-06	8.95e-05	CcSEcCtD
Doxorubicin—Urticaria—Methotrexate—testicular cancer	3.7e-06	8.88e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Methotrexate—testicular cancer	3.68e-06	8.84e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Methotrexate—testicular cancer	3.68e-06	8.84e-05	CcSEcCtD
Doxorubicin—ABCG2—Metabolism—HPGDS—testicular cancer	3.65e-06	0.000551	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—H2AFZ—testicular cancer	3.62e-06	0.000547	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Epirubicin—testicular cancer	3.59e-06	8.62e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Epirubicin—testicular cancer	3.56e-06	8.56e-05	CcSEcCtD
Doxorubicin—Urticaria—Epirubicin—testicular cancer	3.46e-06	8.31e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Epirubicin—testicular cancer	3.44e-06	8.27e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Epirubicin—testicular cancer	3.44e-06	8.27e-05	CcSEcCtD
Doxorubicin—Hypersensitivity—Methotrexate—testicular cancer	3.43e-06	8.24e-05	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—FGFR3—testicular cancer	3.37e-06	0.000508	CbGpPWpGaD
Doxorubicin—Asthenia—Methotrexate—testicular cancer	3.34e-06	8.02e-05	CcSEcCtD
Doxorubicin—ABCC1—Disease—KITLG—testicular cancer	3.33e-06	0.000503	CbGpPWpGaD
Doxorubicin—Pruritus—Methotrexate—testicular cancer	3.29e-06	7.91e-05	CcSEcCtD
Doxorubicin—Hypersensitivity—Epirubicin—testicular cancer	3.21e-06	7.71e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Methotrexate—testicular cancer	3.19e-06	7.65e-05	CcSEcCtD
Doxorubicin—Asthenia—Epirubicin—testicular cancer	3.13e-06	7.51e-05	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—KIT—testicular cancer	3.09e-06	0.000467	CbGpPWpGaD
Doxorubicin—Pruritus—Epirubicin—testicular cancer	3.08e-06	7.4e-05	CcSEcCtD
Doxorubicin—Dizziness—Methotrexate—testicular cancer	3.08e-06	7.39e-05	CcSEcCtD
Doxorubicin—ABCC1—Metabolism—STK11—testicular cancer	3.02e-06	0.000455	CbGpPWpGaD
Doxorubicin—Diarrhoea—Epirubicin—testicular cancer	2.98e-06	7.16e-05	CcSEcCtD
Doxorubicin—Vomiting—Methotrexate—testicular cancer	2.96e-06	7.11e-05	CcSEcCtD
Doxorubicin—Rash—Methotrexate—testicular cancer	2.94e-06	7.05e-05	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—testicular cancer	2.93e-06	7.04e-05	CcSEcCtD
Doxorubicin—CYP1B1—Metabolism—STK11—testicular cancer	2.92e-06	0.00044	CbGpPWpGaD
Doxorubicin—Headache—Methotrexate—testicular cancer	2.92e-06	7e-05	CcSEcCtD
Doxorubicin—Dizziness—Epirubicin—testicular cancer	2.88e-06	6.92e-05	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—FGFR3—testicular cancer	2.85e-06	0.00043	CbGpPWpGaD
Doxorubicin—Vomiting—Epirubicin—testicular cancer	2.77e-06	6.65e-05	CcSEcCtD
Doxorubicin—Nausea—Methotrexate—testicular cancer	2.77e-06	6.64e-05	CcSEcCtD
Doxorubicin—Rash—Epirubicin—testicular cancer	2.75e-06	6.6e-05	CcSEcCtD
Doxorubicin—Dermatitis—Epirubicin—testicular cancer	2.75e-06	6.59e-05	CcSEcCtD
Doxorubicin—Headache—Epirubicin—testicular cancer	2.73e-06	6.55e-05	CcSEcCtD
Doxorubicin—CYP2B6—Metabolism—HPGDS—testicular cancer	2.68e-06	0.000404	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—STK11—testicular cancer	2.65e-06	0.000401	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KIT—testicular cancer	2.61e-06	0.000394	CbGpPWpGaD
Doxorubicin—Nausea—Epirubicin—testicular cancer	2.59e-06	6.21e-05	CcSEcCtD
Doxorubicin—ABCC1—Disease—FGFR3—testicular cancer	2.48e-06	0.000374	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KIT—testicular cancer	2.27e-06	0.000343	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—HPGDS—testicular cancer	1.98e-06	0.000298	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—STK11—testicular cancer	1.95e-06	0.000294	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—HPGDS—testicular cancer	1.86e-06	0.000281	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—STK11—testicular cancer	1.44e-06	0.000217	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—STK11—testicular cancer	1.35e-06	0.000204	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HPGDS—testicular cancer	1.22e-06	0.000184	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—STK11—testicular cancer	8.84e-07	0.000133	CbGpPWpGaD
